# US 2025/0093350 A1 · Fab-linked glycans as biomarker for the transition from a pre disease "at-risk-phase" to rheumatoid arthritis, aav or sjögren syndrome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0093350 A1
- Document ID: US20250093350A1
- Status: Published application
- Kind: A1
- Application number: 18/930,697
- Filed: 2024-10-29
- Published: 2025-03-20
- Earliest claimed: 2016-11-25
- Assignees: Academisch Ziekenhuis Leiden (H.O.D.N. Lumc)
- Applicants: Academisch Ziekenhuis Leiden h.o.d.n. LUMC
- Inventors: Thomas Willem Johannes Huizinga; Reinaldus Everardus Maria Toes; Leendert Adrianus Trouw; Hans Ulrich Scherer
- Web page: https://patentgrep.com/patent/US20250093350A1

## CPC

- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 2800/102: Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
- G01N 2800/328: Vasculitis, i.e. inflammation of blood vessels
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Means and methods for determining whether an individual that does not have rheumatoid arthritis, AAV or Sjögren syndrome at the moment of sampling is at risk of developing the disease, the method comprising determining whether an antibody-containing sample of the individual comprises an autoantibody associated with the disease that comprises an N-linked glycosylation at one or more positions in a Fab-portion of the antibody, the method further comprising determining the risk of the individual for developing the disease. The disease is preferably rheumatoid arthritis.

## Claims

### Claim at position 1

-24. (canceled)

### Claim 25

A kit of parts useful in the detection of an autoantibody associated with rheumatoid arthritis (RA), Sjögren syndrome or anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in a sample, the kit comprising:
a peptide or protein that can bind the autoantibody, and
a molecule that can bind an N-linked glycan on a Fab-portion of an antibody.

### Claim 26 (depends on 25)

The kit of parts of claim 25, wherein the peptide, protein or the molecule that can bind an N-linked glycan is linked to a solid surface.

### Claim at position 4

-28. (canceled)

### Claim 29

A kit of parts useful in detecting an autoantibody associated with rheumatoid arthritis (RA), Sjögren syndrome, or anti-neutrophile cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in a sample, the kit comprising:
a peptide or protein that comprises a modified protein epitope, and
a molecule that can bind an N-linked glycan on a Fab-portion of an antibody.

### Claim 30 (depends on 29)

The kit of claim 29, wherein the modified protein epitope comprises citrulline, homo-citrulline, or acetylated lysine.

### Claim 31 (depends on 29)

The kit of claim 29, wherein the peptide or protein comprises a post-translational modification.

### Claim 32 (depends on 29)

The kit of claim 29, wherein the autoantibody is a citrullinated protein antigen antibody (ACPA)-IgG.

### Claim 33 (depends on 32)

The kit of claim 32, wherein the peptide or the protein is capable of binding to the autoantibody and comprises citrullinated protein antigen.

### Claim 34 (depends on 29)

The kit of claim 29, wherein the glycan-binding molecule comprises sialic acid binding lectin.

### Claim 35 (depends on 34)

The kit of claim 34, wherein the sialic acid binding lectin is Sambucus nigra agglutinin (SNA) or Maackia amurensis agglutinin (MMA).

### Claim 36 (depends on 35)

The kit of claim 35, wherein the peptide, protein, or molecule capable of binding to an N-linked glycan is linked to a solid surface.

### Claim 37 (depends on 29)

The kit of claim 29, wherein the peptide, protein, or molecule capable of binding to an N-linked glycan is linked to a bead.
